An implementation study of treatment optimization recommendations comparing subjects continuing treatment with IFN-β-1a 30 Mcg Qw IM (Avonex) or glatiramer acetate 20 mg Qd SC (Copaxone) to those randomized to IFN-beta-1a 44 Mcg Tiw SC (Rebif), in a multicenter study of subjects with relapsing remitting multiple sclerosis currently on disease-modifying therapy
Latest Information Update: 24 Apr 2013
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 10 Oct 2005 New trial record.